{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/osteoporosis-prevention-of-fragility-fractures/prescribing-information/calcium-colecalciferol-vitamin-d3-preparations/","result":{"pageContext":{"chapter":{"id":"38706564-322f-50d2-a7e2-7fe637b76407","slug":"calcium-colecalciferol-vitamin-d3-preparations","fullItemName":"Calcium and colecalciferol (vitamin D3) preparations","depth":2,"htmlHeader":"<!-- begin field f7c1c00d-f14f-4b6b-b898-3f04ae0b39ea --><h2>Calcium and colecalciferol (vitamin D3) preparations</h2><!-- end field f7c1c00d-f14f-4b6b-b898-3f04ae0b39ea -->","summary":"","htmlStringContent":"<!-- begin item 39e70aa3-2741-4efe-a54d-513c3710a60d --><!-- end item 39e70aa3-2741-4efe-a54d-513c3710a60d -->","topic":{"id":"9f86812a-068c-512b-a1a4-07fda4301d21","topicId":"a4e2c95c-bf7f-4277-b693-c3b2761380ed","topicName":"Osteoporosis - prevention of fragility fractures","slug":"osteoporosis-prevention-of-fragility-fractures","lastRevised":"Last revised in May 2020","chapters":[{"id":"f651cf3f-ec13-5c52-9121-2dd61c54dc3c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"55fa9b49-e88f-5e9b-8156-01352a4c94b5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a36d9df6-8dba-581c-9361-7b771a120859","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0562cda5-80f8-5d79-83f3-f1233a8060e3","slug":"changes","fullItemName":"Changes"},{"id":"8adeb7b7-191a-5ba3-96f4-d25461c0b901","slug":"update","fullItemName":"Update"}]},{"id":"753ec6fc-9992-587b-870c-2a54cddd30c8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"62fbf7e5-b097-5a47-af2f-56553c8b16fb","slug":"goals","fullItemName":"Goals"},{"id":"e2d42919-7f54-594f-bcb8-06f2625a550f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"eca5799e-0969-539e-b27e-e8ed22c5cc54","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"355020b6-9455-5e78-8a1a-172fc947a117","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3c308a4e-8074-5dca-a9bd-a56405a0595f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"745ec600-96ff-5056-8ab4-7ebb02e5286d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4541ac61-d9f8-5c7e-a415-a2f3b57c3f45","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"36908082-d612-5f9e-8dd3-09d9bc87bf79","slug":"definition","fullItemName":"Definition"},{"id":"127d59dc-ce73-51b5-80c0-d57209058280","slug":"causes","fullItemName":"Causes"},{"id":"4349db35-6c86-5ebc-a13f-6a1dce22e466","slug":"complications","fullItemName":"Complications"},{"id":"710ee28b-5971-5b43-ac4e-22ac6fba154d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c62b535b-c8d0-5ce1-93bb-867c8644eb2f","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"35af4f9e-0536-527c-8b94-94cd5f1fa796","fullItemName":"Management","slug":"management","subChapters":[{"id":"bf661812-0f6f-57a2-b0ab-530b799fc4c4","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"85598d9c-79e5-5925-8dee-46b4cd8f2170","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"f0656a98-39c4-59de-aebb-3eebb0d8dc40","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"38706564-322f-50d2-a7e2-7fe637b76407","slug":"calcium-colecalciferol-vitamin-d3-preparations","fullItemName":"Calcium and colecalciferol (vitamin D3) preparations"},{"id":"0d9951b1-3165-5af5-9601-e12d45a17a6c","slug":"bisphosphonates","fullItemName":"Bisphosphonates"}]},{"id":"c086cbd6-b967-579e-9768-901abfa8d3ca","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"726389ef-f472-5512-a1bf-bf15159602fd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f476f450-a081-5a31-a23e-7b837233a18e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"393e0faf-da4e-5bd5-b705-179c32a6c50b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b11023db-83b9-5207-b99c-7917bef26190","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0b683807-10ff-54fc-936a-06d71aa6f8d4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb240203-2f82-5b14-85ec-55933467aceb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"782a2ad0-e9ec-5fc2-b2e1-95ec79f6a2f8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f0656a98-39c4-59de-aebb-3eebb0d8dc40","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"9a167c2e-821e-504c-b556-cdb2b77cdac2","slug":"available-preparations","fullItemName":"Available preparations","depth":3,"htmlHeader":"<!-- begin field baff8dff-8eb7-4f4d-b9cf-ea8e51a41c95 --><h3>What calcium and vitamin D preparations are available?</h3><!-- end field baff8dff-8eb7-4f4d-b9cf-ea8e51a41c95 -->","summary":"","htmlStringContent":"<!-- begin item e105fe3c-a248-4a0c-a607-af98323375a2 --><!-- begin field f4e35be8-1148-49f1-b0c7-c2e4b51e2c8f --><ul><li>There are a number of calcium and vitamin D preparations that provide a daily intake of at least 1 g of calcium and 400 units of vitamin D.</li><li>For people who are allergic to peanuts or soya, preparations which do not contain soya (or soya bean) oil are available, such as Accrete D3<sup>®</sup>, Cacit D3<sup>®</sup>, and Calfovit D3<sup>®</sup>.</li><li>For a complete list of available calcium and vitamin D products and the recommended doses, see the <a data-hyperlink-id=\"19ca115b-26bf-4e74-bd74-a9920174b806\" href=\"https://bnf.nice.org.uk/\" style=\"background-color: rgb(255, 255, 255);\">British National Formulary</a> (BNF). </li></ul><!-- end field f4e35be8-1148-49f1-b0c7-c2e4b51e2c8f --><!-- end item e105fe3c-a248-4a0c-a607-af98323375a2 -->","subChapters":[]},{"id":"c4caa5e3-9f7b-52ba-9274-99b78ab8ec4e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7cf98fcf-0587-4a56-964d-2f2af281071e --><h3>What are the contraindications and cautions for calcium and vitamin D preparations?</h3><!-- end field 7cf98fcf-0587-4a56-964d-2f2af281071e -->","summary":"","htmlStringContent":"<!-- begin item 59576001-d1b0-45f7-a657-2f1247c5a151 --><!-- begin field 021ce730-9533-48b5-a133-c15f01705a5b --><ul><li><strong>Do not prescribe calcium and vitamin D preparations to people with:</strong><ul><li>Any disease or condition that results in hypercalcaemia and/or hypercalciuria (for example some malignancies, such as myeloma).</li><li>Hyperparathyroidism.</li><li>Renal stone disease.</li><li>Hypervitaminosis D.</li><li>Severe chronic kidney disease (chronic kidney disease [CKD] stage 4 or 5).</li><li>An allergy to peanuts or soya — soya oil-free products are available.</li></ul></li><li><strong>Prescribe calcium and vitamin D preparations with caution to people with:</strong><ul><li>Mild to moderate CKD (stages 2–3B) or mild hypercalciuria. Manufacturers recommend periodic checks of plasma calcium levels. <ul><li>In patients with severe renal failure (creatinine clearance of less than 30 ml/minute) dosage adjustments may be necessary.</li></ul></li><li>A history of renal stone disease. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Micromedex, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">BNF 70, 2015</a>]</p><!-- end field 021ce730-9533-48b5-a133-c15f01705a5b --><!-- end item 59576001-d1b0-45f7-a657-2f1247c5a151 -->","subChapters":[]},{"id":"7db04a6d-67f3-5564-b315-f3e554802298","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3bec738e-58c9-4f6f-bc02-e200a0f23afe --><h3>What are the adverse effects of calcium and vitamin D preparations?</h3><!-- end field 3bec738e-58c9-4f6f-bc02-e200a0f23afe -->","summary":"","htmlStringContent":"<!-- begin item 2125ce3a-9f72-426c-b1b4-f01d1cf6be60 --><!-- begin field 6684ff27-4649-4fbe-a215-4be960485ff1 --><ul><li><strong>Adverse effects are uncommon and are generally related to the calcium content of the preparation. </strong>They include: <ul><li>Gastrointestinal adverse effects (such as — constipation, flatulence, nausea, abdominal pain, and diarrhoea).</li><li>Hypercalciuria (and rarely hypercalcaemia) — may occur with long term use of high doses of calcium and vitamin D preparations.</li><li>Hypersensitivity reactions (such as angio-oedema and laryngeal oedema).</li></ul></li><li><strong>Vitamin D supplements</strong> can cause occasional skin rashes.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Micromedex, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">BNF 70, 2015</a>]</p><!-- end field 6684ff27-4649-4fbe-a215-4be960485ff1 --><!-- end item 2125ce3a-9f72-426c-b1b4-f01d1cf6be60 -->","subChapters":[]},{"id":"7fc4372a-617c-583d-ae91-9426da096cb7","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 83574766-73f6-48e5-a46c-3370bf8890f3 --><h3>What are the key drug interactions with calcium and vitamin D preparations?</h3><!-- end field 83574766-73f6-48e5-a46c-3370bf8890f3 -->","summary":"","htmlStringContent":"<!-- begin item a0fa4f8c-2a47-4599-b073-ddcecebe953e --><!-- begin field 87a3225a-9c64-46a6-b10f-c42dd1e0db20 --><ul><li><strong>The key drug interactions with calcium and vitamin D preparations include:</strong> <ul><li><strong>Oral bisphosphonates</strong> — reduced absorption of bisphosphonates. Advise the person to avoid administration at the same time, and to leave a gap of at least 30 minutes. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/prescribing-information/bisphosphonates/#advice\">What advice should I give someone taking bisphosphonates?</a>.</li><li><strong>Strontium ranelate</strong> — reduced absorption of strontium ranelate. Strontium ranelate should be taken 2 hours before or after calcium supplements.</li><li><strong>Quinolones and tetracyclines </strong>— reduced absorption of quinolones and tetracyclines. Quinolones should be taken at least 2 hours before taking a calcium supplement. Tetracyclines should be taken at least 2–3 hours before taking a calcium supplement.</li><li><strong>Levothyroxine, iron, and zinc</strong> — reduced absorption. These drugs should be taken at least 2 hours before taking a calcium supplement.</li><li><strong>Digoxin</strong> — increased effects of digoxin. Some manufacturers of calcium supplements recommend monitoring an ECG and renal function during long-term calcium supplementation, to check for cardiac arrhythmias.</li><li><strong>Thiazide diuretics</strong> — reduced urinary calcium excretion. Due to the increased risk of hypercalcaemia:<ul><li>Monitor serum calcium levels regularly during concomitant use of thiazide diuretics with calcium and vitamin D preparations.</li><li>Some manufacturers of calcium supplements recommend monitoring renal function during long-term calcium supplementation in people also taking a thiazide diuretic.</li></ul></li><li><strong>Oral corticosteroids</strong> — reduced calcium absorption. It may be necessary to increase the dose of the calcium and vitamin D preparations.</li><li><strong>Phenytoin or barbiturates (long-term use)</strong> — there have been a few reports of decreased effects of vitamin D (due to an increase in its metabolism). Consider monitoring for vitamin D deficiency as a higher dose of vitamin D may be required.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Baxter and Preston, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Micromedex, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">BNF 70, 2015</a>]</p><!-- end field 87a3225a-9c64-46a6-b10f-c42dd1e0db20 --><!-- end item a0fa4f8c-2a47-4599-b073-ddcecebe953e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}